The improvements in ovulation rate, visceral adiposity, and insulin sensitivity observed in the SPIOMET arms of the included trials mirror findings from earlier non-randomized trials and cohort studies that advocate for early metabolic intervention in PCOS management [21]. This evidence concerns the gene INS and polycystic ovary syndrome.